HCC: Achieving Complete Response in a Patient After Liver Transplantation, Metastatic Hepatocellular Carcinoma with Sorafenib Treatment and Radiotherapy Continued with Follow-up

Hepatocellular carcinoma (HCC) is the third-leading cause of cancer-associated mortality worldwide, accounting for more than 700000 deaths per year [1]. A large proportion of these patients are not candidates for potentially curative therapy, including liver transplantation or local ablation therapy, as they are diagnosed with advanced or metastatic disease.